News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

ClinTec GmbH Expands into China, Singapore and Thailand, Increasing its Presence in the Emerging Markets for Clinical Research

6/16/2011 8:06:34 AM

16 June 2011 -- UK based Global Clinical Research Organisation (CRO), ClinTec International has continued its international expansion by opening fully registered offices in China, Singapore and Thailand - consolidating its presence in the Asia Pacific region. Over the next quarter, strategic moves into South Korea, Taiwan, Malaysia and Indonesia will also take place. The expansion has also been strengthened by the recent appointment of several regional CRAs plus Mary Pan, Director Asia Pacific who has over 12 years international experience in clinical research.

ClinTec CEO, President and Founder, Dr Buttar commented, “Since ClinTec was established in 1997, entering into the emerging markets has always proved to be a huge success for us and we expect the same from the Asia Pacific market. Several multinational companies in pharmaceutical and clinical nutrition product development are already working in partnership with ClinTec to undertake significant clinical research projects across the region.

Whilst other CROs have tended to acquire local companies in Asia Pacific to expand their geographical presence, ClinTec has remained true to its strategy of organic growth and employing its own local staff members and therefore guaranteeing the same ClinTec culture, values and international standards in the region from the start of its operations. This has also allowed us to offer clients a high degree of flexibility in choosing the most suitable personnel for their projects, aligning our growth with those of our clients. Following a decade of building a strong regional hub in Bangalore, India, we are now tactically located in further Asian countries to meet big pharma’s global need for core resources including talent, experience and a wealth of localised clinical research knowledge.”

In the current economic climate, pharmaceutical companies are searching for new ways of working and delivering global solutions. As such, they are increasingly looking to enter new markets where revenues have not yet been fully tapped, and for partnerships with global CROs capable of facilitating world-wide multicentre clinical research needs. In the past 2 years, ClinTec has entered 25 new countries worldwide and its success has been founded on global experience, combined with local knowledge.

About ClinTec International

ClinTec International is a global contract clinical research organisation, established in 1997 by Dr Rabinder Buttar, the company’s President and CEO. ClinTec International has a presence in 40 developed and emerging countries, covering Western Europe, Central & Eastern Europe, the Middle East and North Africa, Central and South Africa, Latin America, India and the US.

In addition to ClinTec International’s vast expertise in oncology, the organisation has also conducted over 250 clinical trials in other therapeutic areas including anti-infectives, cardiology, dermatology, gastroenterology, neurology, respiratory medicine and rheumatology. ClinTec International excels in conducting clinical studies in diverse geographical locations, supported by a team of world-class project managers and clinical research associates. ClinTec International’s ‘fast, flexible and focused? approach to clinical research ensures an added advantage to the drug development process. The organisations range of services includes Clinical Monitoring and Project Management, Regulatory Affairs, Medical Writing, Data Management and Biostatistics, Global Clinical Resourcing, Quality Assurance, Drug Development Consultancy and Clinical Training courses.

For further information please contact:

Bobby Bal, Senior Director Corporate Development, ClinTec International Headquarters: +44 (0) 141 226 1120 or

For more information about ClinTec, please visit

For media enquiries, please contact Tristan Jervis on +44 (0) 207 861 3019. E-mail:

Read at
Read at ChinaBio Today

comments powered by Disqus